Panacea Biotec gains after announcing shortage of Cilamin 250 Capsule

Panacea Biotec rose 3.38% to Rs 120.90 at 10:14 IST on BSE after the company announced shortage of life saving drug Cilamin 250 Capsule in the retail market.

The announcement was made after market hours yesterday, 28 September 2016.

Meanwhile, the BSE Sensex was up 100.83 points, or 0.36%, to 28,393.64.

On BSE, so far 25,000 shares were traded in the counter, compared with average daily volume of 18,653 shares in the past one quarter. The stock hit a high of Rs 124 and a low of Rs 118.25 so far during the day. The stock hit a 52-week high of Rs 171.20 on 4 December 2015. The stock hit a 52-week low of Rs 83.90 on 12 February 2016. The stock had outperformed the market over the past 30 days till 28 September 2016, rising 7.29% compared with 0.18% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 6.44% as against Sensex's 4.79% rise.

The small-cap company has equity capital of Rs 6.13 crore. Face value per share is Re 1.

Panacea Biotec said Cilamin 250 Capsule, used for treatment of Wilsons disease, Rheumatoid Arthritis and other conditions, witnessed short supply in the market during the last few months due to non-availability of raw material D-Penicillamine in India. Panacea Biotec said that its brand Cilamin 250 Capsules has been made available in limited quantities in the retail market. The temporary shortage is due to sudden disruption of supplies of raw material by qualified supplier beyond the control of the company. Since then company has been working tirelessly with alternate suppliers for supply of this raw material. Due to continuous efforts, the company has resumed limited production of Cilamin 250 and have released limited quantities in the market from 26 September 2016 from the company's manufacturing facility at Baddi under Good Manufacturing Practices.

The firm said it continues to work closely with existing and potential new raw material suppliers in China and India for access to the raw material in an accelerated manner. The company said it is in touch with Drug Controller General of India office for allowing imports of raw material in parallel to registration process under this emergency situation to ensure continuous access of this medicine to patients while other alternative sources in India are being also worked upon in an aggressive manner. As per current estimates, the company expects additional 2-4 weeks for access to additional quantities of raw material and additional 4 weeks for Cilamin 250 supplies to normalize.

Panacea Biotec said it is committed to do what all it takes to ensure continuous and sustainable access of good quality Cilamin 250 a critical lifesaving drug to patients.

Panacea Biotec reported net loss of Rs 19.67 crore in Q1 June 2016 as against net loss of Rs 36.90 crore in Q1 June 2015. Net sales declined 0.3% to Rs 120.40 crore in Q1 June 2016 over Q1 June 2015.

Panacea Biotec is one of India's leading research based biotechnology company established research, manufacturing and marketing capabilities. Panacea Biotec is one of the largest vaccine producer in India and has been amongst the top 3 biotechnology companies and the top 50 pharmaceutical companies in India.

Powered by Capital Market - Live News